Because of the limited knowledge of the molecular pathogenesis of NAFLD, the current therapeutic modalities consist of strategies aimed at decreasing the incidence of the known risk factors.
These combined modalities consisted of IL-2 with or without gp100 peptide vaccination [27], IL-2 combined with stereotactic radiotherapy (RT) [28], IL-2 combined with anti-CTLA4 antibody ipilimumab [29] and IL-2 combined with infusion of ex vivo expanded tumour-infiltrating lymphocytes [30].
The aim of the present study was to evaluate the effectiveness and safety of a combined-treatment modality consisting of systemic chemotherapy with 24-h continuous infusional gemcitabine and mitomycin C, plus external beam radiotherapy in patients with localized unresectable adenocarcinoma of the pancreas.
An additional experimental modality consisting of samples collected 73HAT was included in the RNA-Seq experiment.
In this study we evaluated a novel combination therapy modality consisting of oral α-TEA and HER2/ neu-specific antibody.
Common treatment modalities consist mainly of surgery, radiation therapy, chemotherapy, hormone therapy, and HER2-targeted treatment.
There is a report that combined modality therapy consisting of chemotherapy including bleomycin, etoposide, and cisplatin along with surgery and irradiation may result in a complete response [5].
The acquisitions were performed using a tri-modality setup consisting of a GE Discovery 750 w 3T MR system located in an adjacent room to a GE Discovery 690 ToF PET/CT (GE Healthcare, Waukesha, WI, USA).
This combined modality treatment consisting of accelerated hyperfractionated radiotherapy and chemotherapy turned out to be feasible for patients with locally advanced, irresectable pancreatic cancer.
In conclusion, combined modality treatment consisting of induction therapy with cisplatin, docetaxel and concurrent thoracic irradiation followed by surgery is feasible and effective in patients with LA-NSCLC.
